Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Neurocentrx appoints two members to the board

Nigel Brooksby and Dr Tim Corn join the pharma group

- PMLiVE

Open Access Consulting appoints new director

Jayne Hurrell joins the group from Evidera

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

Alexion adds to pipeline rebuild with $855m Wilson buy

Also acquires the Swedish group’s lead product for Wilson’s disease

Impact of data sharing

With the General Data Protection Regulation (GDPR) on the horizon, the Cambridge Analytica scandal has provided a stark reminder of the importance of data protection laws.

Dovetail

- PMLiVE

GSK hands rare disease assets over to Orchard

The UK pharma group will take a 19.9% stake in its ex-rival

- PMLiVE

Editas Medicine names James Mullen as chairman

He has previously served as CEO of Patheon

- PMLiVE

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

- PMLiVE

Accelerating diagnosis in rare disease

Biopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.

- PMLiVE

Is agile working benefiting the employee or the organisation?

The late Stephen Hawking’s quote, “Intelligence is the ability to adapt to change” really resonates with me when thinking about agile working.We are undoubtedly living through a fundamental transformation in...

No incentive for a cure

The paradox of ‘cost-effective but unaffordable’ life-saving medicines

- PMLiVE

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Interim data suggested there was no improvement on disease-free survival compared to placebo

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links